Concepedia

Author

Atharva Karulkar

Indian Institute of Technology BombayORCID

Also Known As

A. Karulkar, Atharva Karulkar

37

Publications

387

Citations

10

H-Index

19

Concepts

All Affiliations

Indian Institute of Technology BombayTata Memorial HospitalHomi Bhabha National InstituteTopiwala National Medical College & BYL Nair Charitable HospitalNational Institutes of Health
AK

About

Atharva Karulkar is an author at Indian Institute of Technology Bombay specializing in biomedical engineering, skin substitute, and regenerative biomaterials.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Engineering

1

1

15

2

Medicine

1

1

15

3

Biomedical Engineering

1

1

15

4

Cell Biology

1

1

15

5

Regenerative Medicine

1

1

15

Atharva Karulkar

×

7

Publications

132

Citations

7

H-Index

YearCitations

Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells

Alka Dwivedi, Atharva Karulkar, Sarbari Ghosh,

Molecular Cancer Therapeutics

2021

31

The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients

Sushant Kumar, Bhavuk Dhamija, Soumitra Marathe,

Molecular Cancer Research

2020

28

Differential Influence of IL-9 and IL-17 on Actin Cytoskeleton Regulates the Migration Potential of Human Keratinocytes

Sreya Das, Srisathya Srinivasan, Ankita Srivastava,

The Journal of Immunology

2019

21

Hydrogel scaffold with substrate elasticity mimicking physiological-niche promotes proliferation of functional keratinocytes

Pankaj Mogha, Ankita Srivastava, Sushant Kumar,

RSC Advances

2019

15

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Atharva Karulkar, Hasmukh Jain, Shreshtha Shah,

Blood

2022

13

IL-9 Abrogates the Metastatic Potential of Breast Cancer by Controlling Extracellular Matrix Remodeling and Cellular Contractility

Sreya Das, Vishakha Surve, Soumitra Marathe,

The Journal of Immunology

2021

12

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra,

Blood

2023

12

Page 1